[go: up one dir, main page]

WO2000041508A3 - Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines - Google Patents

Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines Download PDF

Info

Publication number
WO2000041508A3
WO2000041508A3 PCT/US2000/001002 US0001002W WO0041508A3 WO 2000041508 A3 WO2000041508 A3 WO 2000041508A3 US 0001002 W US0001002 W US 0001002W WO 0041508 A3 WO0041508 A3 WO 0041508A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune cells
cancer
stimulatory molecules
cytokines
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/001002
Other languages
French (fr)
Other versions
WO2000041508A2 (en
Inventor
Shu-Hsia Chen
Savio L C Woo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Priority to AU32093/00A priority Critical patent/AU3209300A/en
Publication of WO2000041508A2 publication Critical patent/WO2000041508A2/en
Publication of WO2000041508A3 publication Critical patent/WO2000041508A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods and compositions for the treatment, prevention or inhibition of diseases and disorders, including cancer, inflammatory diseases or disorders, and infectious diseases, comprising compounds which augment activated immune cells, i.e., T-cells and natural killer ('NK') cells. In particular, the present invention relates to methods and compositions for the treatment, prevention or inhibition of diseases and disorders, including cancer, inflammatory diseases or disorders, and infectious diseases, comprising the administration of a compound that activates one or more cytokine receptors and a compound that activates one or more co-stimulatory molecules expressed by activated immune cells, i.e., activated T-cells.
PCT/US2000/001002 1999-01-15 2000-01-14 Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines Ceased WO2000041508A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU32093/00A AU3209300A (en) 1999-01-15 2000-01-14 Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11599299P 1999-01-15 1999-01-15
US60/115,992 1999-01-15

Publications (2)

Publication Number Publication Date
WO2000041508A2 WO2000041508A2 (en) 2000-07-20
WO2000041508A3 true WO2000041508A3 (en) 2000-11-02

Family

ID=22364611

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001002 Ceased WO2000041508A2 (en) 1999-01-15 2000-01-14 Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines

Country Status (2)

Country Link
AU (1) AU3209300A (en)
WO (1) WO2000041508A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629683T3 (en) 1999-11-30 2017-08-14 Mayo Foundation For Medical Education And Research B7-H1, a new immunoregulatory molecule
EP1434596B1 (en) * 2001-10-09 2009-07-08 Mayo Foundation For Medical Education And Research Enhancement of immune responses by agonist 4-1bb-antibodies
DE10248141B4 (en) 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nucleic acids and their use for gene therapy
CA2510309C (en) 2002-12-16 2014-09-16 Liyange P. Perera Recombinant vaccine viruses expressing il-15 and methods of using the same
JP5303146B2 (en) 2004-10-06 2013-10-02 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ B7-H1 and methods for diagnosis, prognosis and treatment of cancer
EA024701B1 (en) 2010-04-13 2016-10-31 Селлдекс Терапьютикс Инк. Antibodies that bind human cd27 and uses thereof
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3470081A1 (en) 2013-10-01 2019-04-17 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
JP7466459B2 (en) 2018-04-17 2024-04-12 セルデックス セラピューティクス インコーポレイテッド Anti-CD27 and Anti-PD-L1 Antibodies and Bispecific Constructs
EP3873500A4 (en) 2018-10-31 2023-01-11 Mayo Foundation for Medical Education and Research CANCER TREATMENT METHODS AND MATERIALS
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CARROLL, MILES W. ET AL: "Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen.", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), (DEC. 16, 1998) VOL. 90, NO. 24, PP. 1881-1887., XP000909585 *
CHEMICAL ABSTRACTS, vol. 132, Columbus, Ohio, US; abstract no. 288382, MARTINET, OLIVIER ET AL: "Long-term remission of preestablished hepatic metastases from colorectal cancer by in vivo adenoviral-mediated transfer of interleukin-12 and 4-1BB ligand genes" XP002139305 *
CHONG, H. ET AL: "Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity.", GENE THERAPY, (FEB., 1998) VOL. 5, NO. 2, PP. 223-232., XP000909569 *
CHU N R ET AL: "Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28- T cells.", JOURNAL OF IMMUNOLOGY, (1997 APR 1) 158 (7) 3081-9., XP000887236 *
COUDERC, BETTINA ET AL: "Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.", CANCER GENE THERAPY, (MAY-JUNE, 1998) VOL. 5, NO. 3, PP. 163-175., XP000886763 *
GUO, Z. S. (1) ET AL: "Interleukin 12 and B7.1 costimulatory molecules coexpressed from an adenoviral vector act synergistically to induce antitumor response and suppress tumor formation in Lewis lung carcinoma model.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1999) VOL. 40, PP. 255. MEETING INFO.: 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PHILADELPHIA, PENNSYLVANIA, USA APRIL 10-14, 1999 AMERICAN, XP000887341 *
KIM, YOUNG-JUNE ET AL: "Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses.", EUROPEAN JOURNAL OF IMMUNOLOGY, (MARCH, 1998) VOL. 28, NO. 3, PP. 881-890., XP000909420 *
MELERO I ET AL: "Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors", NATURE MEDICINE,US,NATURE PUBLISHING, CO, vol. 3, no. 6, June 1997 (1997-06-01), pages 682 - 685-685, XP002104261, ISSN: 1078-8956 *
PUTZER, BRIGITTE M. ET AL: "Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997) VOL. 94, NO. 20, PP. 10889-10894., XP000887254 *
SURG. FORUM (1999), 50, 297-299 *

Also Published As

Publication number Publication date
WO2000041508A2 (en) 2000-07-20
AU3209300A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
WO2000041508A3 (en) Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
EP2561874A3 (en) Pharmaceutical compositions for treating cancer
WO2005009355A3 (en) Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
CA2505128A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2004006858A3 (en) Compounds, compositions, and methods employing same
IL146950A0 (en) Recombinant anti-cd40 antibody and uses thereof
WO2005018555A3 (en) Lipid-modified immune response modifiers
AU2003301190A1 (en) Administration of capsaicinoids
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2004103274A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2005079195A3 (en) Pyrazolopyridines and analogs thereof
EP1352897A3 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
WO2005048935A3 (en) Methods of modulating immunity
YU60900A (en) Novel crystalline forms of an antiviral benzimidazole compound
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
WO2002072021A3 (en) Agents and methods for the prevention of initial onset and recurrence of existing cancers
WO2001014395A3 (en) Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
WO2002062952A3 (en) Non-cytotoxic pap mutants
AU2001232854A1 (en) Free radical scavengers or promoters thereof as therapeutic adjuvants in pretermparturition
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
WO2003061572A3 (en) Anti-inflammatory formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase